公开(公告)号：US12233158B2

公开(公告)日：2025-02-25

申请号：US17831150

申请日：2022-06-02

Applicant: Quest Products, LLC

Inventor： Jeffrey T. Haley

IPC: A61K9/00 ,  A23L33/21 ,  A23P10/28 ,  A23P20/20 ,  A23P30/10 ,  A61K31/05 ,  A61K31/465 ,  A61K31/522 ,  A61K31/728 ,  A61K36/28

Abstract: Orally adhering lozenges comprising soluble dietary fiber are provided herein. The orally adhering lozenges provided herein may be in the form of tablet-type lozenges comprising compressed powders and/or granules in at least two layers. The orally adhering lozenges include at least 30% soluble dietary fiber. The orally adhering lozenges also include an adhesive component to adhere the lozenge inside the mouth. The orally adhering lozenges are also low in cariogenic sugar, non-resistant starch, and polyols.

公开(公告)号：US12194063B2

公开(公告)日：2025-01-14

申请号：US18433467

申请日：2024-02-06

Applicant: BEIJING UNIVERSITY OF CHINESE MEDICINE

Inventor： Anlong Xu ,  Hongmei Li

IPC: A61K35/60 ,  A61K31/343 ,  A61K31/661 ,  A61K31/704 ,  A61K31/7048 ,  A61K35/30 ,  A61K35/32 ,  A61K35/50 ,  A61K36/258 ,  A61K36/28 ,  A61K36/296 ,  A61K36/424 ,  A61K36/481 ,  A61K36/537 ,  A61K38/02 ,  A61K38/18 ,  A61P9/00

Abstract: The invention discloses a traditional Chinese medicine mixture with a function of promoting directional differentiation of stem cells into cardiomyocytes, which comprises syngnathus, cornu cervi pantotrichum, hippocampus, ginseng, astragalus, epimedium, placenta hominis, salvia miltiorrhiza, gynostemma pentaphyllum and saussurea involucrata. The invention discloses a traditional Chinese medicine effective ingredient compound with a function of promoting directional differentiation of stem cells into cardiomyocytes. The invention further discloses a chemical compound with a function of promoting directional differentiation of stem cells into cardiomyocytes, which is a brand-new chemical compound from a mixture of velvet antler polypeptide, a syngnathus extract and a hippocampus extract—a new isomer of iridoid glycoside Scropolioside D. The invention further discloses uses of the mixture, the compound and the chemical compound in preparation of a drug or a kit for promoting directional differentiation of stem cells into cardiomyocytes and in scientific research.

公开(公告)号：US20250009831A1

公开(公告)日：2025-01-09

申请号：US18262924

申请日：2022-01-28

Applicant: AKHYNEX S.R.L.

Inventor： Ezio Bombardelli ,  Elena Lombardo

IPC: A61K36/539 ,  A61K36/28 ,  A61K36/752 ,  A61K45/06

Abstract: Disclosed is a combination of Scutellaria extracts with Citrus bergamia or Cynara cardunculus extracts, which is useful for the prevention and treatment of fatty liver disease.

公开(公告)号：US12156878B1

公开(公告)日：2024-12-03

申请号：US18395565

申请日：2023-12-23

Applicant: SAFETY SHOT, INC.

Inventor： David Sandler ,  Jarrett Boon ,  John Gulyas ,  Gregory Blackman

IPC: A23L2/52 ,  A61K9/00 ,  A61K31/137 ,  A61K31/145 ,  A61K31/194 ,  A61K31/197 ,  A61K31/198 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/4748 ,  A61K31/51 ,  A61K31/522 ,  A61K31/525 ,  A61K31/675 ,  A61K31/7068 ,  A61K31/714 ,  A61K31/732 ,  A61K36/258 ,  A61K36/28 ,  A61K36/288 ,  A61K36/48 ,  A61K47/02 ,  A61K47/12 ,  A61P25/32

Abstract: A composition includes a plurality of ingredients, which when combined, have the unexpected effect of accelerating the removal of alcohol from an individual as observed by breathalyzer. The removal occurs at a much faster rate than under normal physiological means. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames. This same composition may also increase mental acuity in a person not suffering from alcohol intoxication.

公开(公告)号：US12156521B2

公开(公告)日：2024-12-03

申请号：US18457035

申请日：2023-08-28

Applicant: 95 Applications, L.L.C.

Inventor： Tony Gonzales ,  Aaron Gonzales

IPC: A01M29/30 ,  A01N25/02 ,  A61K8/58 ,  A61K8/891 ,  A61K8/92 ,  A61K36/185 ,  A61K36/28 ,  A61K36/61 ,  A61K36/738 ,  A61K36/752 ,  A61K45/06 ,  A61K47/24 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/08 ,  B32B37/12 ,  C09D163/00 ,  E04B1/72

Abstract: A barrier system includes a substantially vertical structure representing an exterior surface of a home. The barrier system also includes a coating layer disposed over and circumscribing at least 80% of the substantially vertical structure. The coating layer is in the form of a band and the substantially vertical structure includes an upper region above the coating layer that is free of the coating layer. The coating layer has a height of at least 0.25 inches, has a dried film thickness of at least 5 mils, and has an average surface roughness (Ra) of less than 10 microns.

公开(公告)号：US12128128B2

公开(公告)日：2024-10-29

申请号：US16499406

申请日：2018-03-29

Applicant: Phyto Sophos Ltd.

Inventor： Laura Dewar

IPC: A61K8/9789 ,  A61K8/02 ,  A61K8/19 ,  A61K8/9741 ,  A61K8/9755 ,  A61K8/9783 ,  A61K8/9794 ,  A61K9/00 ,  A61K33/38 ,  A61K36/11 ,  A61K36/14 ,  A61K36/185 ,  A61K36/25 ,  A61K36/258 ,  A61K36/28 ,  A61K36/29 ,  A61K36/30 ,  A61K36/36 ,  A61K36/38 ,  A61K36/48 ,  A61K36/66 ,  A61K36/70 ,  A61K36/74 ,  A61K36/886 ,  A61L26/00 ,  A61P17/02 ,  A61Q19/00

CPC classification number: A61K8/9789 ,  A61K8/0208 ,  A61K8/19 ,  A61K8/9794 ,  A61Q19/00

Abstract: In one aspect, a composition for topical application is provided. The composition comprises a base. Dispersed within the base is elemental silver as a colloidal suspension, and plant extract from at least 6 plants. The plants are selected from the group consisting of Echinacea purpurea, Stellaria media, Aloe vera, Matricaria recutita, Hypericum perforatum, Calendula officinalis, Equisetum arvense, Symphytum officinale, Panax ginseng, Rumex crispus, Arctium lappa, Trifolium pratense, Chelidonium majus, Thuja occidentalis, Urtica dioica, Mahonia aquifolium, and Galium aparine.

公开(公告)号：US20240335496A1

公开(公告)日：2024-10-10

申请号：US18421911

申请日：2024-01-24

Applicant: INFINITUS (CHINA) COMPANY LTD.

Inventor： Lei XIAO ,  Lingling HE ,  Jinlian HUANG ,  Yan GAO

IPC: A61K36/718 ,  A61K9/00 ,  A61K9/06 ,  A61K36/28 ,  A61K36/346 ,  A61K36/42 ,  A61K36/484 ,  A61K36/53 ,  A61K36/539 ,  A61K36/725 ,  A61K36/752 ,  A61K36/808 ,  A61K36/88 ,  A61K36/9068 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38 ,  A61P1/04

CPC classification number: A61K36/718 ,  A61K9/006 ,  A61K9/06 ,  A61K36/28 ,  A61K36/346 ,  A61K36/42 ,  A61K36/484 ,  A61K36/53 ,  A61K36/539 ,  A61K36/725 ,  A61K36/752 ,  A61K36/808 ,  A61K36/88 ,  A61K36/9068 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38 ,  A61P1/04 ,  A61K2236/15 ,  A61K2236/53

Abstract: The present invention is related to a modified prescription of Gancao Xiexin decoction and the use thereof. The modified prescription of Gancao Xiexin decoction of the present invention mainly contains Coptidis Rhizoma, Scutellariae Radix, Glycyrrhizae Radix et Rhizoma, Zingiberis Rhizoma, Jujubae Fructus, Citri Reticulatae Pericarpium and Bolbostemmatis Rhizoma with effects of alleviating inflammatory reaction and promoting oral healing, and can be used for treating oral ulcer or for preparing a product for treating oral ulcer, which helps reduce the recurrence of oral ulcer. Meanwhile, the present invention also provides a soft gel containing the aqueous extract of the modified prescription of Gancao Xiexin decoction, which has a simple composition, does not contain toxic traditional Chinese medicine, can be administered by coating oral ulcer, is convenient to use and has a good therapeutic effect.

公开(公告)号：US12097231B2

公开(公告)日：2024-09-24

申请号：US18328066

申请日：2023-06-02

Applicant: CARGILL, INCORPORATED

Inventor： Dan S. Gaspard ,  Adam John Steinbach ,  Adam T. Zarth

IPC: A23L27/30 ,  A23F3/34 ,  A23L2/56 ,  A23L2/60 ,  A23L2/68 ,  A23L5/40 ,  A23L27/00 ,  A61K31/192 ,  A61K31/235 ,  A61K36/28 ,  B01D15/36 ,  C07H15/256 ,  C07K1/16 ,  C07K1/18

CPC classification number: A61K36/28 ,  A23F3/34 ,  A23L2/56 ,  A23L2/60 ,  A23L2/68 ,  A23L5/40 ,  A23L27/30 ,  A23L27/36 ,  A23L27/39 ,  A23L27/88 ,  A61K31/192 ,  A61K31/235 ,  B01D15/361 ,  C07H15/256 ,  C07K1/16 ,  C07K1/18 ,  A23V2002/00 ,  A23V2200/15 ,  A23V2250/258 ,  A61K2236/31 ,  A61K2236/39

Abstract: A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to reduce surface tension. Method for reducing surface tension in a steviol glycoside solution includes contacting a steviol glycoside and a surface tension reducing compound.

公开(公告)号：US12090185B2

公开(公告)日：2024-09-17

申请号：US17813724

申请日：2022-07-20

Applicant: SUPER CRITICAL IP, LLC

Inventor： Armand J. Noel

IPC: C07D311/80 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  A61K36/28 ,  C07C37/00 ,  C07C37/74 ,  C07C37/84

CPC classification number: A61K36/28 ,  A61K31/05 ,  A61K31/352 ,  A61K36/185 ,  C07C37/003 ,  C07C37/74 ,  C07C37/84 ,  C07D311/80 ,  A61K2236/35 ,  A61K2236/37 ,  A61K2236/51 ,  A61K2236/53 ,  C07B2200/13 ,  C07C2601/16

Abstract: Some variations provide a process of converting a cannabinoid into a purified cannabinoid derivative, comprising: providing a starting composition comprising a cannabinoid; providing a C9-C11 non-aromatic hydrocarbon solvent; introducing the starting composition and the solvent to a conversion reactor; chemically converting some, but not all, of the cannabinoid to a cannabinoid derivative, generating a reaction mixture containing unreacted cannabinoid; conveying the reaction mixture to a crystallization unit; cooling the reaction mixture to precipitate unreacted cannabinoid out of the reaction mixture, thereby generating a mother liquor containing the cannabinoid derivative; and isolating and recovering the cannabinoid derivative from the mother liquor. Systems configured to carry out the disclosed processes are also provided. This invention offers a large-scale solution to economically convert CBD to D9-THC, among many other example. The principles of the invention may be applied to the conversion of various cannabinoids and terpenes into derivative products.

公开(公告)号：US20240293489A1

公开(公告)日：2024-09-05

申请号：US18664874

申请日：2024-05-15

Applicant: Housey Pharmaceutical Research Laboratories, L.L.C.

Inventor： Gerard M. Housey ,  Monica Elizabeth Balash

IPC: A61K36/28 ,  A61K31/155 ,  A61K31/40 ,  A61K31/4985 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  G01N33/50

CPC classification number: A61K36/28 ,  A61K31/155 ,  A61K31/40 ,  A61K31/4985 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  G01N33/5008 ,  A61K2300/00 ,  G01N2333/4703 ,  G01N2500/10

Abstract: This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible curc of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and/or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and/or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body.